Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Abstract Background Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with...

Full description

Bibliographic Details
Main Authors: Luis M. Pérez-Belmonte, José David Torres-Peña, María D. López-Carmona, M. Mar. Ayala-Gutiérrez, Francisco Fuentes-Jiménez, Lucía Jorge Huerta, Jaime Alonso Muñoz, Manuel Rubio-Rivas, Manel Madrazo, Marcos Guzmán Garcia, Beatriz Vicente Montes, Joaquim Fernández Sola, Javier Ena, Ruth Gonzalez Ferrer, Carmen Mella Pérez, Carlos Jorge Ripper, Jose Javier Napal Lecumberri, Iris El Attar Acedo, Susana Plaza Canteli, Sara Fuente Cosío, Francisco Amorós Martínez, Begoña Cortés Rodríguez, Pablo Pérez-Martínez, José Manuel Ramos-Rincón, Ricardo Gómez-Huelgas, for the SEMI-COVID-19 Network
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Medicine
Subjects:
Type 2 diabetes mellitus
Glucose-lowering drug
Coronavirus disease 2019
Online Access:http://link.springer.com/article/10.1186/s12916-020-01832-2

Internet

http://link.springer.com/article/10.1186/s12916-020-01832-2

Similar Items